Premium
Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders
Author(s) -
Reading Richard
Publication year - 2005
Publication title -
child: care, health and development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.832
H-Index - 82
eISSN - 1365-2214
pISSN - 0305-1862
DOI - 10.1111/j.1365-2214.2005.00504_4.x
Subject(s) - risperidone , irritability , placebo , somnolence , psychology , autism , adverse effect , clinical global impression , psychiatry , pervasive developmental disorder , extrapyramidal symptoms , pediatrics , medicine , developmental disorder , anxiety , schizophrenia (object oriented programming) , antipsychotic , alternative medicine , pathology
Risperidone in the treatment of disruptive behavioural symptoms in children with autistic and other pervasive developmental disorders.
Shea S , Turgay A , Carroll A , Schulz M , Orlik H , Smith I & Dunbar F.(2004)Pediatrics,114,e634–e641.Objective To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioural symptoms in children with autism and other pervasive developmental disorders (PDD). Methods In this 8‐week, randomized, double‐blinded, placebo‐controlled trial, risperidone/placebo solution (0.01–0.06 mg/kg/day) was administered to 79 children who were aged 5–12 years and had PDD. Behavioural symptoms were assessed using the Aberrant Behaviour Checklist (ABC), Nisonger Child Behaviour Rating Form and Clinical Global Impression‐Change. Safety assessments included vital signs, electrocardiogram, extrapyramidal symptoms, adverse events and laboratory tests. Results Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the ABC (primary endpoint) compared with those who were taking placebo. By study endpoint, risperidone‐treated subjects exhibited a 64% improvement over baseline in the irritability score almost double that of placebo‐treated subjects (31%). Risperidone‐treated subjects also exhibited significantly greater decreases on the other four subscales of the ABC; on the conduct problem, insecure/anxious, hyperactive and overly sensitive subscales of the Nisonger Child Behaviour Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom. More risperidone‐treated subjects (87%) showed global improvement in their condition compared with the placebo group (40%). Somnolence, the most frequently reported adverse event, was noted in 72.5% vs. 7.7% of subjects (risperidone vs. placebo) and seemed manageable with dose/dose‐schedule modification. Risperidone‐treated subjects experienced statistically significantly greater increases in weight (2.7 vs. 1.0 kg), pulse rate and systolic blood pressure. Extrapyramidal symptoms scores were comparable between groups. Conclusions Risperidone was well‐tolerated and efficacious in treating behavioural symptoms associated with PDD in children.